State Street’s ProKidney PROK Stock Holding History

State Street’s Portfolio PROK Stock Details PROK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$3.01M	Buy	1,810,345 +764,400	+73%	+$1.29M	﹤0.01%	3280
2026 Q2	$2.13M	Buy	1,045,945 +489,100	+88%	+$895K	﹤0.01%	3374
2026 Q1	$997K	Buy	556,845 +76,500	+16%	+$162K	﹤0.01%	3488
2025 Q4	$1.08M	Buy	480,345 +5,388	+1%	+$14.2K	﹤0.01%	3516
2025 Q3	$1.15M	Buy	474,957 +121,350	+34%	+$323K	﹤0.01%	3479
2025 Q2	$209K	Sell	353,607 -1,372,716	-80%	-$1.07M	﹤0.01%	3821
2025 Q1	$1.51M	Sell	1,726,323 -11,541	-0.7%	-$16K	﹤0.01%	3334
2024 Q4	$2.94M	Buy	1,737,864 +309,546	+22%	+$558K	﹤0.01%	3186
2024 Q3	$2.74M	Buy	1,428,318 +198,836	+16%	+$451K	﹤0.01%	3210
2024 Q2	$3.02M	Buy	1,229,482 +286,883	+30%	+$770K	﹤0.01%	3141
2024 Q1	$1.55M	Sell	942,599 -38,792	-4%	-$57K	﹤0.01%	3359
2023 Q4	$1.75M	Buy	981,391 +73,544	+8%	+$158K	﹤0.01%	3355
2023 Q3	$4.16M	Sell	907,847 -82,412	-8%	-$789K	﹤0.01%	3012
2023 Q2	$11.1M	Buy	990,259 +929,878	+1,540%	+$9.9M	﹤0.01%	2596
2023 Q1	$684K	Buy	60,381 +9,258	+18%	+$98.5K	﹤0.01%	3645
2022 Q4	$351K	Buy	+51,123	New	+$488K	﹤0.01%	3891

Other funds holding PROK

Morgan Stanley New York $1.96T AUM 27.49% 1-Year Est. Return

BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Propel Bio Management Los Angeles, California $189M AUM 71.31% 1-Year Est. Return

Bleichroeder LP New York $1.02B AUM 33% 1-Year Est. Return

Hennion & Walsh Asset Management Parsippany, New Jersey $3.42B AUM 25.82% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM

Brown University Providence, Rhode Island $147M AUM 5.01% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $463B AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM

State Street's PROK Position: Q3 2026 in Review

State Street increased its ProKidney (PROK) stake by 73% in Q3 2026, buying an estimated $1.29M and bringing the position to 1,810,345 shares worth $3.01M. The position accounts for ﹤0.01% of the portfolio, ranked #3280.

State Street first reported a position in PROK in Q4 2022 and has held it in 16 quarters since. The position peaked at $11.1M in Q2 2023. 67 funds tracked by Wall St. Rank hold PROK as of Q3 2026.

State Street held 1,810,345 shares of ProKidney worth $3.01M as of Q3 2026.
State Street bought 764,400 ProKidney shares in Q3 2026, an estimated $1.29M.
ProKidney made up ﹤0.01% of State Street's portfolio in Q3 2026, its #3280 holding.
State Street first reported a position in ProKidney in Q4 2022 and has held it in 16 quarters since.
State Street's ProKidney position peaked at $11.1M in Q2 2023.
67 funds tracked by Wall St. Rank held ProKidney as of Q3 2026.

Based on State Street's 13F filing for Q3 2026, filed 12 Nov 2026.